REPORT ID 4865

Asia-Pacific Multiple Sclerosis (MS) Drugs Market Report 2019

Publish Date
2019
Pages
112
Format
Electronic (PDF)

In this report, the Asia-Pacific Multiple Sclerosis (MS) Drugs market is valued at USD   XX million in 2019 and is expected to reach USD  XX million by the end of 2025, growing at a CAGR of  XX% between 2019 and 2025.

Geographically, this report split Asia-Pacific into several key Regions, with sales (K Pcs), revenue (Million USD), market share and growth rate of Multiple Sclerosis (MS) Drugs for these regions, from   2019 to 2025 (forecast), including
    China
    Japan
    South Korea
    Taiwan
    India
    Southeast Asia
    Australia

Asia-Pacific Multiple Sclerosis (MS) Drugs market competition by top manufacturers/players, with Multiple Sclerosis (MS) Drugs sales volume, price, revenue (Million USD) and market share for each manufacturer/player; the top players including
    Bayer AG
    Bayhill Therapeutics
    Biogen Idec
    Cinnagen
    Daiichi Sankyo
    Eli Lilly
    Fast Forward Llc
    Antisense Therapeutics
    Apitope
    Five Prime Therapeutics
    Genmab
    Artielle Immunotherapeutics
    Genzyme
    Glaxosmithkline
    Gw Pharmaceuticals
    Innate Immunotherapeutics

On the basis of product, this report displays the sales volum, revenue, product price, market share and growth rate of each type, primarily split into
    Copaxone (Glatiramer Acetate, Copolymer 1)
    Novantrone (Mitoxantrone)
    Gilenya (Fingolimod, Fty720)
    Aubagio (Teriflunomide)
    Tecfidera (Dimethyl Fumarate)
    Firategrast (Sb683699, T-0047)
    Siponimod (Baf312)
    Others

On the basis on the end users/applications, this report focuses on the status and outlook for major applications/end users, sales volume, market share and growth rate for each application, including
    RRMS
    SPMS
    PPMS
    PRMS

If you have any special requirements, please let us know and we will offer you the report as you want.

 
			   
Table of Contents

Asia-Pacific Multiple Sclerosis (MS) Drugs Market  Report 2019
1 Multiple Sclerosis (MS) Drugs Overview
    1.1 Product Overview and Scope of Multiple Sclerosis (MS) Drugs
    1.2 Classification of Multiple Sclerosis (MS) Drugs by Product Category
        1.2.1 Asia-Pacific Multiple Sclerosis (MS) Drugs Market Size (Sales) Comparison by Types ( 2014-2024)
        1.2.2 Asia-Pacific Multiple Sclerosis (MS) Drugs Market Size (Sales) Market Share by Type (Product Category)  in 2018
        1.2.3 Copaxone (Glatiramer Acetate, Copolymer 1)
        1.2.4 Novantrone (Mitoxantrone)
        1.2.5 Gilenya (Fingolimod, Fty720)
        1.2.6 Aubagio (Teriflunomide)
        1.2.7 Tecfidera (Dimethyl Fumarate)
        1.2.8 Firategrast (Sb683699, T-0047)
        1.2.9 Siponimod (Baf312)
        1.2.10 Others
    1.3 Asia-Pacific Multiple Sclerosis (MS) Drugs Market by Application/End Users
        1.3.1 Asia-Pacific Multiple Sclerosis (MS) Drugs Sales (Volume) and Market Share Comparison by Applications ( 2014-2024)
        1.3.2 RRMS
        1.3.3 SPMS
        1.3.4 PPMS
        1.3.5 PRMS
    1.4 Asia-Pacific Multiple Sclerosis (MS) Drugs Market by Region
        1.4.1 Asia-Pacific Multiple Sclerosis (MS) Drugs Market Size (Value) Comparison by Region ( 2014-2024)
        1.4.2 China Status and Prospect ( 2014-2024)
        1.4.3 Japan Status and Prospect ( 2014-2024)
        1.4.4 South Korea Status and Prospect ( 2014-2024)
        1.4.5 Taiwan Status and Prospect ( 2014-2024)
        1.4.6 India Status and Prospect ( 2014-2024)
        1.4.7 Southeast Asia Status and Prospect ( 2014-2024)
        1.4.8 Australia Status and Prospect ( 2014-2024)
    1.5 Asia-Pacific Market Size (Value and Volume) of Multiple Sclerosis (MS) Drugs ( 2014-2024)
        1.5.1 Asia-Pacific Multiple Sclerosis (MS) Drugs Sales and Growth Rate ( 2014-2024)
        1.5.2 Asia-Pacific Multiple Sclerosis (MS) Drugs Revenue and Growth Rate ( 2014-2024)

2 Asia-Pacific Multiple Sclerosis (MS) Drugs Competition by Players/Suppliers, Region, Type and Application
    2.1 Asia-Pacific Multiple Sclerosis (MS) Drugs Market Competition by Players/Suppliers
        2.1.1 Asia-Pacific Multiple Sclerosis (MS) Drugs Sales Volume and Market Share of Key Players/Suppliers ( 2014-2019)
        2.1.2 Asia-Pacific Multiple Sclerosis (MS) Drugs Revenue and Share by Players/Suppliers ( 2014-2019)
    2.2 Asia-Pacific Multiple Sclerosis (MS) Drugs (Volume and Value) by Type
        2.2.1 Asia-Pacific Multiple Sclerosis (MS) Drugs Sales and Market Share by Type ( 2014-2019)
        2.2.2 Asia-Pacific Multiple Sclerosis (MS) Drugs Revenue and Market Share by Type ( 2014-2019)
    2.3 Asia-Pacific Multiple Sclerosis (MS) Drugs (Volume) by Application
    2.4 Asia-Pacific Multiple Sclerosis (MS) Drugs (Volume and Value) by Region
        2.4.1 Asia-Pacific Multiple Sclerosis (MS) Drugs Sales and Market Share by Region ( 2014-2019)
        2.4.2 Asia-Pacific Multiple Sclerosis (MS) Drugs Revenue and Market Share by Region ( 2014-2019)

3 China Multiple Sclerosis (MS) Drugs (Volume, Value and Sales Price)
    3.1 China Multiple Sclerosis (MS) Drugs Sales and Value ( 2014-2019)
        3.1.1 China Multiple Sclerosis (MS) Drugs Sales Volume and Growth Rate ( 2014-2019)
        3.1.2 China Multiple Sclerosis (MS) Drugs Revenue and Growth Rate ( 2014-2019)
        3.1.3 China Multiple Sclerosis (MS) Drugs Sales Price Trend ( 2014-2019)
    3.2 China Multiple Sclerosis (MS) Drugs Sales Volume and Market Share by Type
    3.3 China Multiple Sclerosis (MS) Drugs Sales Volume and Market Share by Application

4 Japan Multiple Sclerosis (MS) Drugs (Volume, Value and Sales Price)
    4.1 Japan Multiple Sclerosis (MS) Drugs Sales and Value ( 2014-2019)
        4.1.1 Japan Multiple Sclerosis (MS) Drugs Sales Volume and Growth Rate ( 2014-2019)
        4.1.2 Japan Multiple Sclerosis (MS) Drugs Revenue and Growth Rate ( 2014-2019)
        4.1.3 Japan Multiple Sclerosis (MS) Drugs Sales Price Trend ( 2014-2019)
    4.2 Japan Multiple Sclerosis (MS) Drugs Sales Volume and Market Share by Type
    4.3 Japan Multiple Sclerosis (MS) Drugs Sales Volume and Market Share by Application

5 South Korea Multiple Sclerosis (MS) Drugs (Volume, Value and Sales Price)
    5.1 South Korea Multiple Sclerosis (MS) Drugs Sales and Value ( 2014-2019)
        5.1.1 South Korea Multiple Sclerosis (MS) Drugs Sales Volume and Growth Rate ( 2014-2019)
        5.1.2 South Korea Multiple Sclerosis (MS) Drugs Revenue and Growth Rate ( 2014-2019)
        5.1.3 South Korea Multiple Sclerosis (MS) Drugs Sales Price Trend ( 2014-2019)
    5.2 South Korea Multiple Sclerosis (MS) Drugs Sales Volume and Market Share by Type
    5.3 South Korea Multiple Sclerosis (MS) Drugs Sales Volume and Market Share by Application

6 Taiwan Multiple Sclerosis (MS) Drugs (Volume, Value and Sales Price)
    6.1 Taiwan Multiple Sclerosis (MS) Drugs Sales and Value ( 2014-2019)
        6.1.1 Taiwan Multiple Sclerosis (MS) Drugs Sales Volume and Growth Rate ( 2014-2019)
        6.1.2 Taiwan Multiple Sclerosis (MS) Drugs Revenue and Growth Rate ( 2014-2019)
        6.1.3 Taiwan Multiple Sclerosis (MS) Drugs Sales Price Trend ( 2014-2019)
    6.2 Taiwan Multiple Sclerosis (MS) Drugs Sales Volume and Market Share by Type
    6.3 Taiwan Multiple Sclerosis (MS) Drugs Sales Volume and Market Share by Application

7 India Multiple Sclerosis (MS) Drugs (Volume, Value and Sales Price)
    7.1 India Multiple Sclerosis (MS) Drugs Sales and Value ( 2014-2019)
        7.1.1 India Multiple Sclerosis (MS) Drugs Sales Volume and Growth Rate ( 2014-2019)
        7.1.2 India Multiple Sclerosis (MS) Drugs Revenue and Growth Rate ( 2014-2019)
        7.1.3 India Multiple Sclerosis (MS) Drugs Sales Price Trend ( 2014-2019)
    7.2 India Multiple Sclerosis (MS) Drugs Sales Volume and Market Share by Type
    7.3 India Multiple Sclerosis (MS) Drugs Sales Volume and Market Share by Application

8 Southeast Asia Multiple Sclerosis (MS) Drugs (Volume, Value and Sales Price)
    8.1 Southeast Asia Multiple Sclerosis (MS) Drugs Sales and Value ( 2014-2019)
        8.1.1 Southeast Asia Multiple Sclerosis (MS) Drugs Sales Volume and Growth Rate ( 2014-2019)
        8.1.2 Southeast Asia Multiple Sclerosis (MS) Drugs Revenue and Growth Rate ( 2014-2019)
        8.1.3 Southeast Asia Multiple Sclerosis (MS) Drugs Sales Price Trend ( 2014-2019)
    8.2 Southeast Asia Multiple Sclerosis (MS) Drugs Sales Volume and Market Share by Type
    8.3 Southeast Asia Multiple Sclerosis (MS) Drugs Sales Volume and Market Share by Application

9 Australia Multiple Sclerosis (MS) Drugs (Volume, Value and Sales Price)
    9.1 Australia Multiple Sclerosis (MS) Drugs Sales and Value ( 2014-2019)
        9.1.1 Australia Multiple Sclerosis (MS) Drugs Sales Volume and Growth Rate ( 2014-2019)
        9.1.2 Australia Multiple Sclerosis (MS) Drugs Revenue and Growth Rate ( 2014-2019)
        9.1.3 Australia Multiple Sclerosis (MS) Drugs Sales Price Trend ( 2014-2019)
    9.2 Australia Multiple Sclerosis (MS) Drugs Sales Volume and Market Share by Type
    9.3 Australia Multiple Sclerosis (MS) Drugs Sales Volume and Market Share by Application

10 Asia-Pacific Multiple Sclerosis (MS) Drugs Players/Suppliers Profiles and Sales Data
    10.1 Bayer AG
        10.1.1 Company Basic Information, Manufacturing Base and Competitors
        10.1.2 Multiple Sclerosis (MS) Drugs Product Category, Application and Specification
            10.1.2.1 Product A
            10.1.2.2 Product B
        10.1.3 Bayer AG Multiple Sclerosis (MS) Drugs Sales, Revenue, Price and Gross Margin ( 2014-2019)
        10.1.4 Main Business/Business Overview
    10.2 Bayhill Therapeutics
        10.2.1 Company Basic Information, Manufacturing Base and Competitors
        10.2.2 Multiple Sclerosis (MS) Drugs Product Category, Application and Specification
            10.2.2.1 Product A
            10.2.2.2 Product B
        10.2.3 Bayhill Therapeutics Multiple Sclerosis (MS) Drugs Sales, Revenue, Price and Gross Margin ( 2014-2019)
        10.2.4 Main Business/Business Overview
    10.3 Biogen Idec
        10.3.1 Company Basic Information, Manufacturing Base and Competitors
        10.3.2 Multiple Sclerosis (MS) Drugs Product Category, Application and Specification
            10.3.2.1 Product A
            10.3.2.2 Product B
        10.3.3 Biogen Idec Multiple Sclerosis (MS) Drugs Sales, Revenue, Price and Gross Margin ( 2014-2019)
        10.3.4 Main Business/Business Overview
    10.4 Cinnagen
        10.4.1 Company Basic Information, Manufacturing Base and Competitors
        10.4.2 Multiple Sclerosis (MS) Drugs Product Category, Application and Specification
            10.4.2.1 Product A
            10.4.2.2 Product B
        10.4.3 Cinnagen Multiple Sclerosis (MS) Drugs Sales, Revenue, Price and Gross Margin ( 2014-2019)
        10.4.4 Main Business/Business Overview
    10.5 Daiichi Sankyo
        10.5.1 Company Basic Information, Manufacturing Base and Competitors
        10.5.2 Multiple Sclerosis (MS) Drugs Product Category, Application and Specification
            10.5.2.1 Product A
            10.5.2.2 Product B
        10.5.3 Daiichi Sankyo Multiple Sclerosis (MS) Drugs Sales, Revenue, Price and Gross Margin ( 2014-2019)
        10.5.4 Main Business/Business Overview
    10.6 Eli Lilly
        10.6.1 Company Basic Information, Manufacturing Base and Competitors
        10.6.2 Multiple Sclerosis (MS) Drugs Product Category, Application and Specification
            10.6.2.1 Product A
            10.6.2.2 Product B
        10.6.3 Eli Lilly Multiple Sclerosis (MS) Drugs Sales, Revenue, Price and Gross Margin ( 2014-2019)
        10.6.4 Main Business/Business Overview
    10.7 Fast Forward Llc
        10.7.1 Company Basic Information, Manufacturing Base and Competitors
        10.7.2 Multiple Sclerosis (MS) Drugs Product Category, Application and Specification
            10.7.2.1 Product A
            10.7.2.2 Product B
        10.7.3 Fast Forward Llc Multiple Sclerosis (MS) Drugs Sales, Revenue, Price and Gross Margin ( 2014-2019)
        10.7.4 Main Business/Business Overview
    10.8 Antisense Therapeutics
        10.8.1 Company Basic Information, Manufacturing Base and Competitors
        10.8.2 Multiple Sclerosis (MS) Drugs Product Category, Application and Specification
            10.8.2.1 Product A
            10.8.2.2 Product B
        10.8.3 Antisense Therapeutics Multiple Sclerosis (MS) Drugs Sales, Revenue, Price and Gross Margin ( 2014-2019)
        10.8.4 Main Business/Business Overview
    10.9 Apitope
        10.9.1 Company Basic Information, Manufacturing Base and Competitors
        10.9.2 Multiple Sclerosis (MS) Drugs Product Category, Application and Specification
            10.9.2.1 Product A
            10.9.2.2 Product B
        10.9.3 Apitope Multiple Sclerosis (MS) Drugs Sales, Revenue, Price and Gross Margin ( 2014-2019)
        10.9.4 Main Business/Business Overview
    10.10 Five Prime Therapeutics
        10.10.1 Company Basic Information, Manufacturing Base and Competitors
        10.10.2 Multiple Sclerosis (MS) Drugs Product Category, Application and Specification
            10.10.2.1 Product A
            10.10.2.2 Product B
        10.10.3 Five Prime Therapeutics Multiple Sclerosis (MS) Drugs Sales, Revenue, Price and Gross Margin ( 2014-2019)
        10.10.4 Main Business/Business Overview
    10.11 Genmab
    10.12 Artielle Immunotherapeutics
    10.13 Genzyme
    10.14 Glaxosmithkline
    10.15 Gw Pharmaceuticals
    10.16 Innate Immunotherapeutics

11 Multiple Sclerosis (MS) Drugs Manufacturing Cost Analysis
    11.1 Multiple Sclerosis (MS) Drugs Key Raw Materials Analysis
        11.1.1 Key Raw Materials
        11.1.2 Price Trend of Key Raw Materials
        11.1.3 Key Suppliers of Raw Materials
        11.1.4 Market Concentration Rate of Raw Materials
    11.2 Proportion of Manufacturing Cost Structure
        11.2.1 Raw Materials
        11.2.2 Labor Cost
        11.2.3 Manufacturing Expenses
    11.3 Manufacturing Process Analysis of Multiple Sclerosis (MS) Drugs

12 Industrial Chain, Sourcing Strategy and Downstream Buyers
    12.1 Multiple Sclerosis (MS) Drugs Industrial Chain Analysis
    12.2 Upstream Raw Materials Sourcing
    12.3 Raw Materials Sources of Multiple Sclerosis (MS) Drugs Major Manufacturers  in 2018
    12.4 Downstream Buyers

13 Marketing Strategy Analysis, Distributors/Traders
    13.1 Marketing Channel
        13.1.1 Direct Marketing
        13.1.2 Indirect Marketing
        13.1.3 Marketing Channel Development Trend
    13.2 Market Positioning
        13.2.1 Pricing Strategy
        13.2.2 Brand Strategy
        13.2.3 Target Client
    13.3 Distributors/Traders List

14 Market Effect Factors Analysis
    14.1 Technology Progress/Risk
        14.1.1 Substitutes Threat
        14.1.2 Technology Progress in Related Industry
    14.2 Consumer Needs/Customer Preference Change
    14.3 Economic/Political Environmental Change

15 Asia-Pacific Multiple Sclerosis (MS) Drugs Market Forecast ( 2019-2025)
    15.1 Asia-Pacific Multiple Sclerosis (MS) Drugs Sales Volume, Revenue and Price Forecast ( 2019-2025)
        15.1.1 Asia-Pacific Multiple Sclerosis (MS) Drugs Sales Volume and Growth Rate Forecast ( 2019-2025)
        15.1.2 Asia-Pacific Multiple Sclerosis (MS) Drugs Revenue and Growth Rate Forecast ( 2019-2025)
        15.1.3 Asia-Pacific Multiple Sclerosis (MS) Drugs Price and Trend Forecast ( 2019-2025)
    15.2 Asia-Pacific Multiple Sclerosis (MS) Drugs Sales Volume, Revenue and Growth Rate Forecast by Region ( 2019-2025)
        15.2.1 Asia-Pacific Multiple Sclerosis (MS) Drugs Sales Volume and Growth Rate Forecast by Region ( 2019-2025)
        15.2.2 Asia-Pacific Multiple Sclerosis (MS) Drugs Revenue and Growth Rate Forecast by Region ( 2019-2025)
        15.2.3 China Multiple Sclerosis (MS) Drugs Sales, Revenue and Growth Rate Forecast ( 2019-2025)
        15.2.4 Japan Multiple Sclerosis (MS) Drugs Sales, Revenue and Growth Rate Forecast ( 2019-2025)
        15.2.5 South Korea Multiple Sclerosis (MS) Drugs Sales, Revenue and Growth Rate Forecast ( 2019-2025)
        15.2.6 Taiwan Multiple Sclerosis (MS) Drugs Sales, Revenue and Growth Rate Forecast ( 2019-2025)
        15.2.7 India Multiple Sclerosis (MS) Drugs Sales, Revenue and Growth Rate Forecast ( 2019-2025)
        15.2.8 Southeast Asia Multiple Sclerosis (MS) Drugs Sales, Revenue and Growth Rate Forecast ( 2019-2025)
        15.2.9 Australia Multiple Sclerosis (MS) Drugs Sales, Revenue and Growth Rate Forecast ( 2019-2025)
    15.3 Asia-Pacific Multiple Sclerosis (MS) Drugs Sales, Revenue and Price Forecast by Type ( 2019-2025)
        15.3.1 Asia-